Frequency Electronics reported earnings of 34 cents per share for the fourth quarter, up from 28 cents per share in the ...

Frequency Therapeutics is using novel progenitor cell stimulating technology to regrow hair cells in the ear and improve hearing loss in patients.

What happenedShares of Frequency Therapeutics (NASDAQ: FREQ) were crashing 74.9% as of 11:07 a.m. EDT on Tuesday. The huge drop came after the company announced disappointing top-line interim ...

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, a clinical stage biotechnology company, today announced positive results from a Phase 1/2 safety trial to evaluate FX-322, an ...

Frequency Therapeutics announces the closing of a $32 million Series A financing, led by CoBro Ventures, to develop Progenitor Cell Activation Platfor ...

Frequency Therapeutics, which is developing a regenerative therapy for hearing loss, raised $84 million in a downsized IPO by offering 6 million shares at $14, the low end of the range of $14 ...

Korro Bio plans a reverse merger with Frequency Therapeutics to fund clinical studies of its lead candidate, designed to treat alpha-1 antitrypsin deficiency (AATD) in the liver.

Frequency Therapeutics reported its first-quarter 2020 results displaying continued ample liquidity. The company simultaneously updated the market with promising results for FX-322 from its ...

Frequency Therapeutics has discontinued developing its remyelination program for Multiple Sclerosis as it explores strategic alternatives for the program.

Frequency Therapeutics went public on the Nasdaq Global Select Market on October 3, 2019, offering its shares at a price of $14 each. The IPO lock-up period expires on March 31, 2020.

Research out of Woburn-based biotech company Frequency Therapeutics might allow people to regenerate their sense of hearing. Although there’s still years of work to go, researchers say ...